Kim  Kelderman net worth and biography

Kim Kelderman Biography and Net Worth

Insider of Bio-Techne

Kim Kelderman joined Bio-Techne on April 30, 2018 as President, Diagnostics and Genomics. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. For the last three years, Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Kim served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes "Vacutainer" business.

Mr. Kelderman holds a Bachelor of Science degree from Hogeschool Heerlen of Applied Sciences in the Netherlands.

What is Kim Kelderman's net worth?

The estimated net worth of Kim Kelderman is at least $61,076.41 as of May 25th, 2021. Mr. Kelderman owns 811 shares of Bio-Techne stock worth more than $61,076 as of November 2nd. This net worth evaluation does not reflect any other assets that Mr. Kelderman may own. Additionally, Mr. Kelderman receives a salary of $845,710.00 as Insider at Bio-Techne. Learn More about Kim Kelderman's net worth.

How old is Kim Kelderman?

Mr. Kelderman is currently 56 years old. There are 4 older executives and no younger executives at Bio-Techne. The oldest executive at Bio-Techne is Mr. Charles R. Kummeth, Senior Advisor & Director, who is 64 years old. Learn More on Kim Kelderman's age.

What is Kim Kelderman's salary?

As the Insider of Bio-Techne Co., Mr. Kelderman earns $845,710.00 per year. The highest earning executive at Bio-Techne is Mr. Charles R. Kummeth, Senior Advisor & Director, who commands a salary of $1,260,000.00 per year. Learn More on Kim Kelderman's salary.

How do I contact Kim Kelderman?

The corporate mailing address for Mr. Kelderman and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at [email protected]. Learn More on Kim Kelderman's contact information.

Has Kim Kelderman been buying or selling shares of Bio-Techne?

Kim Kelderman has not been actively trading shares of Bio-Techne during the past quarter. Most recently, Kim Kelderman sold 500 shares of the business's stock in a transaction on Friday, November 19th. The shares were sold at an average price of $505.38, for a transaction totalling $252,690.00. Learn More on Kim Kelderman's trading history.

Who are Bio-Techne's active insiders?

Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), John Higgins (Director), James Hippel (CFO), Kim Kelderman (Insider), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.

Are insiders buying or selling shares of Bio-Techne?

In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 10,400 shares worth more than $800,592.00. The most recent insider tranaction occured on March, 7th when Director Roeland Nusse sold 10,400 shares worth more than $800,592.00. Insiders at Bio-Techne own 3.9% of the company. Learn More about insider trades at Bio-Techne.

Information on this page was last updated on 3/7/2024.

Kim Kelderman Insider Trading History at Bio-Techne

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Sell500$505.38$252,690.00View SEC Filing Icon  
9/22/2021Sell822$529.04$434,870.88View SEC Filing Icon  
6/9/2021Sell811$433.00$351,163.00View SEC Filing Icon  
5/25/2021Sell845$424.00$358,280.00811View SEC Filing Icon  
2/5/2021Sell823$388.45$319,694.35845View SEC Filing Icon  
See Full Table

Kim Kelderman Buying and Selling Activity at Bio-Techne

This chart shows Kim Kelderman's buying and selling at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bio-Techne Company Overview

Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $75.31
Low: $74.07
High: $76.48

50 Day Range

MA: $73.69
Low: $68.37
High: $80.36

2 Week Range

Now: $75.31
Low: $52.99
High: $85.57

Volume

983,810 shs

Average Volume

910,102 shs

Market Capitalization

$11.95 billion

P/E Ratio

80.12

Dividend Yield

0.43%

Beta

1.28